N Roche: Grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, personal fees from Teva, personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Mundipharma, personal fees from Cipla, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Sandoz, personal fees from 3M, personal fees from Zambon, outside the submitted work

D Halpin: Personal fees and non-financial support from Boehringer Ingelheim, personal fees from GSK, personal fees from AstraZeneca, personal fees from Pfizer, personal fees and non-financial support from Novartis, personal fees from Chiesi Pharmaceuticals & personal fees from Sandoz.

OS Usmani: Industry-academic funding from Boehringer Ingelheim, Chiesi, Edmond Pharma, GlaxoSmithKline, Mundipharma International, and has received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Edmond Pharma, GlaxoSmithKline, Napp, Novartis, Mundipharma International, Pearl Therapeutics, Roche, Sandoz, Takeda, UCB, Vectura and Zentiva.

G Brussels: Honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Novartis, Pfizer and UCB; he is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis.

S Wan Yau Ming: Employee of OPRI; OPRI did the analyses under contract and with funding from AstraZeneca.

S Halim: Employee of AstraZeneca

G Gopalan: Employee of AstraZeneca

D Price: Board Membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd, UK and 74% of Observational and Pragmatic Research Institute Pte Ltd, Singapore; and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment.

P254

FEASIBILITY OF ULTRASHORT ECHO TIME (UTE) MRI TO EVALUATE THE EFFECT OF LUMACAFTOR/IVACAFTOR THERAPY IN CHILDREN WITH CYSTIC FIBROSIS (CF) HOMOZYGOUS FOR F508DEL

10.1136/thoraxjnl-2017-210983.466

S Nagle reports personal consulting fees from Vertex Pharmaceuticals during the conduct of the study; non-financial support from GE Healthcare (institution/department support).

AS Brody reports personal fees from Vertex Pharmaceuticals during the conduct of the study.

J Woods reports personal consulting fees from Vertex Pharmaceuticals during the conduct of the study.

KM Johnson reports personal consulting fees Vertex Pharmaceuticals during the conduct of the study.

L Wang, G Marigowda, D Waltz, C Hug are employees of Vertex Pharmaceuticals and may hold stock and/or stock options in the company.

J Goldin reports 'other' conflicts – Founder of MedQIA during the conduct of the study.

F Ratjen reports grants and personal fees from Vertex Pharmaceuticals, personal consulting fees from Novartis, Bayer, Roche, Genetech, and Prosteostasis.

P255

RATE OF LUNG FUNCTION DECLINE IN PATIENTS WITH CYSTIC FIBROSIS (CF) HAVING A RESIDUAL FUNCTION GENE MUTATION

10.1136/thoraxjnl-2017-210983.467

G Sawicki reports personal fees from Vertex Pharmaceuticals outside the submitted work. (advisory boards)

MW Konstan, E McKone, RB Moss reports personal consulting fees from Vertex Pharmaceuticals and institutional grant funding from Vertex Pharmaceuticals during the conduct of the study.

B Lubarsky and E Suthoff are employees of Vertex Pharmaceuticals and may hold stock and/or stock options in the company.

S Millar and D Pasta are employees of ICON Clinical Research, which was paid by Vertex Pharmaceuticals for providing analytical services on this project and which is paid by various pharmaceutical, biotechnology, and device companies for providing clinical research services.

N Mayer-Hamblett and CH Goss report institutional grant funding from Vertex Pharmaceuticals during the conduct of the study.

W Morgan reports grants from NIH/NHLBI, grants from NIH/NIAID, grants from Cystic Fibrosis Foundation, personal fees from Cystic Fibrosis Foundation, personal fees from University of Arizona, personal fees from American College of Chest Physicians, personal fees from American Thoracic Society, personal fees from Elsevier outside the submitted work.